SCHEMBL4699192

SCHEMBL4699192

CCC1(c2cc(F)cc(C(N)=O)c2)C2CN(CCCC3(O)CCCCC3)CC21.Cc1ccc(S(=O)(=O)O)cc1

nearest known ligand 0.50

Known targets — ChEMBL curated mechanism

ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
OPRM1 known ✓ P35372 17/20 0.50
OPRD1 P41143 4/20 0.50
OPRK1 P41145 4/20 0.50
KCNH2 Q12809 3/20 0.50
HTR1A P08908 1/20 0.34
DRD1 P21728 1/20 0.34
DRD4 P21917 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
SLC6A4 P31645 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
DRD2 P14416 1/20 0.34
CCR1 P32246 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4697321 0.90 OPRM1 (0.54) OPRM1OPRD1OPRK1KCNH2DRD2
SCHEMBL4699200 0.82 OPRM1 (0.61) OPRM1OPRD1OPRK1KCNH2CCR1
SCHEMBL4702161 0.80 OPRM1 (0.60) OPRM1OPRD1OPRK1KCNH2
SCHEMBL4700297 0.79 OPRM1 (0.68) OPRM1OPRD1OPRK1KCNH2
SCHEMBL4701083 0.78 OPRM1 (0.70) OPRM1OPRD1OPRK1KCNH2
SCHEMBL4697315 0.75 OPRM1 (0.75) OPRM1OPRD1OPRK1KCNH2
SCHEMBL4700090 0.73 OPRM1 (0.59) OPRM1OPRD1OPRK1KCNH2
Citric Acid SCHEMBL4755341 0.71 OPRM1 (0.57) OPRM1OPRD1OPRK1KCNH2
SCHEMBL4755802 0.71 OPRM1 (0.50) OPRM1OPRD1OPRK1KCNH2
SCHEMBL4697748 0.71 OPRM1 (0.71) OPRM1OPRD1OPRK1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1440059-B1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2008-04-16 EP claimed
EP-1440059-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS Pfizer Products Inc. (US) 2004-07-28 EP claimed
US-20030087898-A1 3-azabicyclo[3.1.0]hexane derivatives PFIZER INC. 2003-05-08 US claimed
WO-2003035622-A1 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2003-05-01 WO claimed
EP-1440059-B1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2008-04-16 EP disclosed
US-20070054950-A1 3-Azabicyclo[3.1.0]hexane derivatives PFIZER INC. 2007-03-08 US disclosed
US-7153976-B2 Purification process for an azabicyclo[3.1.0]hexane compound PFIZER INC. (US) 2006-12-26 US disclosed
EP-1678136-A1 PROCESS FOR PREPARING AN AZABICYCLO[3.1.0]HEXANE COMPOUND Pfizer Products Inc. (US) 2006-07-12 EP disclosed
US-7049335-B2 3-azabicyclo[3.1.0]hexane derivatives PFIZER INC. (US) 2006-05-23 US disclosed
US-20050171178-A1 3-Azabicyclo[3.1.0]hexane derivatives PFIZER INC 2005-08-04 US disclosed
WO-2005033080-A1 PROCESS FOR PREPARING AN AZABICYCLO[3.1.0]HEXANE COMPOUND PFIZER PRODUCTS INC. (US) 2005-04-14 WO disclosed
US-20050075387-A1 Process for preparing an azabicyclo[3.1.0] hexane compound PFIZER INC 2005-04-07 US disclosed
EP-1440059-A1 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS Pfizer Products Inc. (US) 2004-07-28 EP disclosed
US-20030087898-A1 3-azabicyclo[3.1.0]hexane derivatives PFIZER INC. 2003-05-08 US disclosed
WO-2003035622-A1 3-AZABICYCLO (3.1.0) HEXANE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087898-A1 3-azabicyclo[3.1.0]hexane derivatives OPRD1, OPRM1, OPRK1 OPRM1 2/4885OPRD1 1/4885OPRK1 3/4885
US-20050171178-A1 3-Azabicyclo[3.1.0]hexane derivatives OPRD1, OPRM1, OPRK1 OPRM1 2/4885OPRD1 1/4885OPRK1 3/4885
US-20070054950-A1 3-Azabicyclo[3.1.0]hexane derivatives OPRD1, OPRM1, OPRK1 OPRM1 2/4885OPRD1 1/4885OPRK1 3/4885
US-20050075387-A1 Process for preparing an azabicyclo[3.1.0] hexane compound AZI2, CYP1B1, CYP4B1 OPRM1 2847/4885OPRD1 1930/4885OPRK1 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.